Campbell & Co Investment Adviser’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Campbell & Co Investment Adviser’s Portfolio MRNS Stock Details MRNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-69,514	Closed	-$628K	–	1411
2024 Q1	$628K	Sell	69,514 -35,869	-34%	-$349K	0.05%	605
2023 Q4	$1.15M	Buy	+105,383	New	+$790K	0.1%	331
2023 Q3	–	Sell	-11,856	Closed	-$129K	–	1235
2023 Q2	$129K	Buy	+11,856	New	+$102K	0.02%	834

Other funds holding MRNS

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

LPC

Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Campbell & Co Investment Adviser's MRNS Position: Q2 2024 in Review

Campbell & Co Investment Adviser sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q2 2024, closing a stake of 69,514 shares — an estimated $628K sold.

Campbell & Co Investment Adviser first reported a position in MRNS in Q2 2023 and held it in 3 quarters. The position peaked at $1.15M in Q4 2023. 90 funds tracked by Wall St. Rank hold MRNS as of Q2 2024.

Campbell & Co Investment Adviser reported no remaining Marinus Pharmaceuticals, Inc position as of Q2 2024 after selling out during the quarter.
Campbell & Co Investment Adviser sold 69,514 Marinus Pharmaceuticals, Inc shares in Q2 2024, an estimated $628K.
Campbell & Co Investment Adviser first reported a position in Marinus Pharmaceuticals, Inc in Q2 2023 and held it in 3 quarters.
Campbell & Co Investment Adviser's Marinus Pharmaceuticals, Inc position peaked at $1.15M in Q4 2023.
90 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q2 2024.

Based on Campbell & Co Investment Adviser's 13F filing for Q2 2024, filed 13 Aug 2024.